Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Castagna

Showing results (101-110 of 203) with videos related to

Pageof 21
Sort By:
Transplantation and Cellular Therapy|June 17, 2022
Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationGiorgia Battipaglia, Myriam Labopin, Didier Blaise, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 10, 2020
Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAnnalisa Ruggeri, Myriam Labopin, Giorgia Battipaglia, et al.
Bone Marrow Transplantation|November 8, 2018
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patientsThomas Pagliardini, Samia Harbi, Sabine Fürst, et al.
Annals of Hematology|January 17, 2012
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO studyLuigi Rigacci, Bendetta Puccini, Anna Dodero, et al.
Mediterranean Journal of Hematology and Infectious Diseases|September 25, 2015
Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideJean El-Cheikh, Roberto Crocchiolo, Andrea Vai, et al.
British Journal of Haematology|August 21, 2018
Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3<sup>+</sup> cellsRaphael Cauchois, Luca Castagna, Thomas Pagliardini, et al.
Transplantation and Cellular Therapy|April 10, 2021
Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis LymphomasLuca Castagna, Anna Dodero, Francesca Patriarca, et al.
Leukemia & Lymphoma|January 14, 2012
Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?Jean El-Cheikh, Roberto Crocchiolo, Jean-Marie Boher, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 28, 2020
Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell TransplantationJean El-Cheikh, Raynier Devillier, Remy Dulery, et al.
Experimental Hematology|March 27, 2012
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myelomaJean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Pageof 21

Showing results (101-110 of 203) with videos related to

Sort By:
Pageof 21
Transplantation and Cellular Therapy|June 17, 2022
Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationGiorgia Battipaglia, Myriam Labopin, Didier Blaise, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 10, 2020
Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAnnalisa Ruggeri, Myriam Labopin, Giorgia Battipaglia, et al.
Bone Marrow Transplantation|November 8, 2018
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patientsThomas Pagliardini, Samia Harbi, Sabine Fürst, et al.
Annals of Hematology|January 17, 2012
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO studyLuigi Rigacci, Bendetta Puccini, Anna Dodero, et al.
Mediterranean Journal of Hematology and Infectious Diseases|September 25, 2015
Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant CyclophosphamideJean El-Cheikh, Roberto Crocchiolo, Andrea Vai, et al.
British Journal of Haematology|August 21, 2018
Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3<sup>+</sup> cellsRaphael Cauchois, Luca Castagna, Thomas Pagliardini, et al.
Transplantation and Cellular Therapy|April 10, 2021
Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis LymphomasLuca Castagna, Anna Dodero, Francesca Patriarca, et al.
Leukemia & Lymphoma|January 14, 2012
Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?Jean El-Cheikh, Roberto Crocchiolo, Jean-Marie Boher, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 28, 2020
Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell TransplantationJean El-Cheikh, Raynier Devillier, Remy Dulery, et al.
Experimental Hematology|March 27, 2012
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myelomaJean El-Cheikh, Roberto Crocchiolo, Sabine Furst, et al.
Pageof 21